Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited disorder of cardiac sarcomeric proteins characterised by the presence of myocardial hypertrophy in the absence of abnormal loading conditions. Individuals with HCM can remain asymptomatic throughout their lives but many experience chest pain, symptoms of heart failure, syncope and sudden ventricular arrhythmias. Cardiopulmonary exercise testing is an important part of the assessment of patients with HCM who often have reduced peak oxygen consumption and a lower anaerobic threshold compared with healthy age-matched controls. This review will focus on mechanisms of exercise limitation, which are complex and multifactorial, and the options for medical management.
Keywords: Hypertrophic cardiomyopathy, exercise capacity, heart failure, left ventricular tract obstruction, ischaemia, metabolism.
Current Pharmaceutical Design
Title:Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy
Volume: 21 Issue: 4
Author(s): V. Patel, C.H. Critoph and P.M. Elliott
Affiliation:
Keywords: Hypertrophic cardiomyopathy, exercise capacity, heart failure, left ventricular tract obstruction, ischaemia, metabolism.
Abstract: Hypertrophic cardiomyopathy (HCM) is an inherited disorder of cardiac sarcomeric proteins characterised by the presence of myocardial hypertrophy in the absence of abnormal loading conditions. Individuals with HCM can remain asymptomatic throughout their lives but many experience chest pain, symptoms of heart failure, syncope and sudden ventricular arrhythmias. Cardiopulmonary exercise testing is an important part of the assessment of patients with HCM who often have reduced peak oxygen consumption and a lower anaerobic threshold compared with healthy age-matched controls. This review will focus on mechanisms of exercise limitation, which are complex and multifactorial, and the options for medical management.
Export Options
About this article
Cite this article as:
Patel V., Critoph C.H. and Elliott P.M., Mechanisms and Medical Management of Exercise Intolerance in Hypertrophic Cardiomyopathy, Current Pharmaceutical Design 2015; 21 (4) . https://dx.doi.org/10.2174/138161282104141204142436
DOI https://dx.doi.org/10.2174/138161282104141204142436 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member
Current Drug Targets Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Glucocorticoid Excess Induces Accumulation of Cardiac Glycogen and Triglyceride: Suggested Role for AMPK
Current Pharmaceutical Design Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology Cardiac Metabolism in Diabetes Mellitus
Current Pharmaceutical Design Relation Between Sleep Quality and Physical Activity in Chronic Heart Failure Patients
Recent Patents on Cardiovascular Drug Discovery Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study
Current Drug Safety Periostin as a Heterofunctional Regulator of Cardiac Development and Disease
Current Genomics Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Editorial[Hot Topic:Stem Cell Therapy for Cardiovascular Diseases:Are We Still at the Beginning of A Long Road?(Guest Editor:Lino M Goncalves)
Cardiovascular & Hematological Disorders-Drug Targets Circulating Biomarkers for the Diagnosis and Prognosis of Heart Failure
Current Medicinal Chemistry The STAT3 Inhibitor Stattic Impairs Cardiomyocyte Mitochondrial Function Through Increased Reactive Oxygen Species Formation
Current Pharmaceutical Design Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology Molecule of the Month
Current Topics in Medicinal Chemistry Editorial (Thematic Issue Title: Myocardial Cell Death: Molecular Mechanisms & Drug Targets)
Cardiovascular & Hematological Agents in Medicinal Chemistry